Healthcare ❯Pharmaceuticals ❯Drug Development

Manufacturing

Clinical Trials Tariffs Cell Therapy U.S. Market

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030

The decision answers potential Trump administration tariffs by bolstering U.S. manufacturing to help meet the company’s goal of half its revenue from America by 2030.

3 ARTICLES

3mo ago

Novartis Announces $23 Billion U.S. Expansion with New Plants and R&D Hub

5 ARTICLES

10mo ago

Eli Lilly to Invest $4.5 Billion in New Indiana Drug Manufacturing Facility